Tag Archives: GLP-1
GLP-1 and Reflux: The Same Signal in 3 Countries
GLP-1 receptor agonists drew a reflux signal in US, Japanese and Canadian databases, with reporting odds ratios running from 2.83 to 4.76.
GLP-1 and Atrial Fibrillation: 10 Reviews, Same Trials
GLP-1 and atrial fibrillation has ten meta-analyses behind it. An umbrella review rated none above low confidence and found the trials heavily shared.
GLP-1 in Serious Mental Illness: 764,115 Matched Pairs
GLP-1 initiation was linked to lower four-year mortality than SGLT2 inhibitors in serious mental illness, and the absolute gap was larger there.
GLP-1 Below BMI 27: Benefit With Little Weight to Lose
GLP-1 receptor agonists cut coded heart failure in type 2 diabetes with a BMI under 27, where there is almost no weight left to lose.
GLP-1 in Ulcerative Colitis: 66.7% vs 25.3% at 12 Weeks
GLP-1 receptor agonist users with ulcerative colitis reached remission far more often than matched controls. Weight loss was not associated with it.
Semaglutide: 6 Years of EU Reports, Two Unsettled Signals
Semaglutide drew more eye and suicidal ideation reports than dulaglutide in EudraVigilance. A 2024 cohort of 240,000 people found the opposite.
Semaglutide and Cognition: 13,007 Records, One Null Result
Semaglutide beat three comparators on a cognitive score in 13,007 psychiatric patients, and tied with the fourth. The fourth also acts on GLP-1.
GLP-1 and Mitochondria: A 2026 Review Maps the Axis
GLP-1 drugs touch mitochondrial biogenesis, dynamics and mitophagy. A 2026 Aging Cell review asks how much of that is the receptor, not weight loss.